Meeting
2023 ASCO Annual Meeting
IMM01 plus tislelizumab in patients with advanced solid tumors and lymphoma: An open-label, multicenter, phase 1b/2 dose escalation and expansion study (IMM01-04).
Authors
Zhengbo Song
Zhejiang Cancer Hospital, Hangzhou, China
Zhengbo Song , Xu Tong , Yan Zhang , Hui Zhu , Yanqiu Zhao , Xiaoqing Yu , Xinghao Ai , Zhenzhen Zong , Xiwen Zhao , Siman Gao , Qiying Lu , Wenzhi Tian , Shun Lu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
PD1/PD-L1 Inhibitor Combinations
Clinical Trial Registration Number
CTR20220791
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2600)
DOI
10.1200/JCO.2023.41.16_suppl.2600
Abstract #
2600
Poster Bd #
442
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
First Author: Jordi Rodon Ahnert
Poster
2022 ASCO Annual Meeting
A multicenter, open-label, phase 1a/b study of HC-7366, a modulator of integrated stress response (ISR) kinase GCN2 in subjects with advanced solid tumors.
First Author: Meredith Pelster
Poster
2021 ASCO Annual Meeting
An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
First Author: Arvind Dasari